Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878103 | PMC |
| http://dx.doi.org/10.1111/jocd.15544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HLA-DR regulatory T cells and IL-10 are associated with success or failure of desensitization outcomes.
Allergy
September 2024
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Background: Omalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated.
View Article and Find Full Text PDFVariations in protocol development during oral immunotherapy.
J Food Allergy
July 2022
From the Allergy and Clinical Immunology Division, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; and.
Oral immunotherapy (OIT) protocols are not standardized, and a wide heterogeneity exists in the literature. OIT protocol variables include the initiation approach (fixed dose versus oral food challenge), buildup speed (slow versus fast), target maintenance dose (low versus high target dose), type of food used, and use of adjuvants among other variables. Most protocols start with an initial escalation day, which is a series of extremely low doses to safely identify the patients who are most allergic, followed by a buildup period over several months to years until the final target maintenance dose is achieved.
View Article and Find Full Text PDFOne-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Int Arch Allergy Immunol
May 2024
Department of Immunology and Allergy, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Introduction: Iron deficiency is the most common cause of anemia in both sexes, although it is more common in women. Intravenous (IV) iron replacement is preferred in patients who cannot tolerate oral treatment or when iron stores need to be replenished rapidly. In this study, we wanted to share the ferric carboxymaltose (FCM) desensitization protocol that we self-created and successfully applied.
View Article and Find Full Text PDFStepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.
Am J Clin Dermatol
May 2023
Institute of Allergology, Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Paul-Ehrlich-Haus, Hindenburgdamm 27, 12203, Berlin, Germany.
In chronic spontaneous urticaria (CSU), wheals, angioedema, or both appear spontaneously for > 6 weeks. Current recommended treatment options for urticaria target mast cell mediators such as histamine, or activators, such as autoantibodies. The goal of CSU treatment is to treat the disease until it is gone as effectively and safely as possible.
View Article and Find Full Text PDFSafety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.
Pediatr Pulmonol
April 2023
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Background: Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID-19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been little investigated.
Objective: To assess the safety of biologics in patients with SARS-CoV-2 infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!